Abstract
In vitro, human Tregs can also acquire a Th1 phenotype when stimulated in the presence of IL-12. This phenotype is characterized by the upregulation of the master regulator of T helper 1 (Th1) cells, T-bet, and some other Th1 markers such as CXCR3 and CCR5, while maintaining Foxp3 expression [6, 9] . IL-12-induced human Th1-Tregs display a defect in suppression as compared to IFNc À Tregs, although they still retain a degree of suppressive capacity ex vivo [6, 9] . Although Th1-Tregs have been observed in different disease settings, the molecular mechanisms and signaling pathways that are involved in their generation and function have not been elucidated, which is a critical step for devising specific therapies to correct losses of immune tolerance observed in autoimmune diseases. Here, we describe the signaling pathway components that are responsible for Th1-Treg generation and function in humans. By using a genome-wide gene expression approach and pathway analysis, we defined the PI3K/AKT/Foxo1/3 as the major pathway involved in IFNc secretion by Tregs. Using an in vitro model of Th1-Treg generation, we confirmed that this pathway is activated during Th1-Treg reprogramming and its modulation by either activation of PI3K or AKT1 or inhibition of PTEN or Foxo1/3 is sufficient for human Tregs to acquire a Th1 phenotype. We further demonstrate the specific and non-overlapping roles of the three AKT isoforms in Th1-Treg generation, demonstrating that while AKT1 inhibition diminishes IFNc secretion, AKT3 silencing is sufficient to induce the Th1 phenotype. The physiological relevance of our observation is confirmed by data demonstrating that the PI3K/AKT/Foxo1/3 pathway is activated in Tregs from untreated RRMS patients as compared to healthy donors in vivo, and blockade of this pathway inhibits IFNc secretion by MS Tregs and restores the defective suppressive function. These data define a fundamental pathway altered in the function of Tregs underlying autoimmune disease potentially amenable to immune targeting.
Results
Ex vivo-isolated IFNc + Tregs possess a specific gene expression signature In order to examine signaling pathways differentially expressed in Th1-Tregs, CD4 + CD25 hi CD127 low/neg Tregs from eight healthy individuals were sorted ex vivo and stimulated for 4 h with PMA and ionomycin to induce IFNc secretion. Tregs were sorted based on the expression of IFNc using an IFNc capture kit, and purity was confirmed by Foxp3 staining as well as IFNG and TBX21 gene expression (Fig EV1) . A genome-wide microarray analysis was performed on IFNc + and IFNc À Treg populations; statistical analysis (see Materials and Methods, GEO accession number GSE71274) identified 4393 genes that were differentially expressed (DEG, P-value cutoff 0.05 and fold change cutoff 1.5). Ingenuity Pathway Analysis elucidated specific signaling pathways enriched in DEGs, listed by order of significance (Fisher's exact test, Appendix Table S1 ). The PI3K/AKT/Foxo1/3 pathway was the most significant, and Fig 1A shows the expression values of selected molecules from this pathway as fold increase/decrease in IFNc + Tregs as compared to IFNc À Tregs. AKT1 and PHLPP2 were significantly upregulated, while AKT2, AKT3, PIK3CA, and PTEN were downregulated. The differential expression of these targets was confirmed by real-time PCR in a new set of IFNc + and IFNc À Tregs isolated from nine healthy individuals ( Fig 1B) .
To examine whether the PI3K/AKT/Foxo1/3 pathway was differentially expressed during Th1-Treg reprogramming, we stimulated Tregs ex vivo with anti-CD3 and anti-CD28 in the presence or absence of IL-12 and gene expression was examined at 24-h intervals for a total of 4 days [6] (Fig 1C) . We observed a significant upregulation of AKT1 and PHLPP2 and a downregulation of AKT2, AKT3, FOXO1, FOXO3, and PTEN gene expression. PIK3CA showed a trend toward downregulation, but it did not reach statistical significance. Gene expression data was confirmed at protein level on IL-12-driven Th1-Tregs (Fig 1D and E) . Interestingly, we observed differential protein expression of the three AKT isoforms, with a significant increase in AKT1 and decreased expression of AKT3 on Th1-Tregs as compared to Tregs (Fig 1E) . Foxo3 and PTEN were both downregulated, while Foxo1 did not show a statistically significant difference in expression in Th1-Tregs as compared to Tregs (data not shown). These data demonstrate that the PI3K/AKT/ Foxo1/3 signaling pathway is differentially expressed during Th1-Treg reprogramming.
PI3K/AKT/Foxo pathway is activated during Th1-Treg generation
We next sought to examine whether the PI3K/AKT/Foxo1/3 pathway was activated during generation of Th1-Tregs. Activation of this pathway starts by different stimuli that trigger a variety of receptors such as T-cell receptor (TCR) [14] , co-stimulatory molecules such as CD28 [15] , cytokine receptors [16] , G protein-coupled receptors (GPCR) [17] , and insulin [18] among others. This initial stimulation causes the phosphorylation and activation of PI3K, which then catalyzes the formation of the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) [19] . PIP3 can then bind PDK1 and AKT, and AKT is activated by PDK1 by phosphorylation on residue Thr 308 [20] , being able to phosphorylate different downstream targets. We hypothesized that during Th1-Treg reprogramming, IL-12 stimulation would activate PDK1, which in turn would phosphorylate AKT. In order to examine this hypothesis, we measured phosphorylation of AKT at Thr 308 after the addition of IL-12 for 50 min by FACS. IL-12 induced AKT phosphorylation as early as 20 min after stimulation (Fig 2A) , and this increase was maintained for 20 additional minutes (Appendix Fig S1) .
Once activated, AKT phosphorylates many downstream targets, among them the transcription factors Foxo1 and Foxo3 [21] . We thus examined the phosphorylation status of Foxo1 and Foxo3 upon IL-12 stimulation and observed that IL-12 induced a significant increase in the phosphorylation of both transcription factors as compared to Tregs treated with vehicle (Fig 2A) . Interestingly, the increased phosphorylation of AKT, Foxo1, and Foxo3 was observed not only at short time points after IL-12 addition, but also 16 h after stimulation with anti-CD3 and anti-CD28 in the presence of IL-12 as compared to vehicle (Fig 2B and C) , suggesting that the activation of the pathway is maintained during Th1-Treg reprogramming.
Foxo1 and Foxo3 reside in the nucleus of Tregs, where they help maintain Foxp3 expression and suppressive capacity [22] . When phosphorylated by AKT, they are excluded from the nucleus and thus not able to regulate their transcriptional targets [23] . We hypothesized that IL-12-driven phosphorylation of Foxo1 and Foxo3 would exclude them from the nucleus, thus preventing regulation of their transcriptional targets. Foxo1 positively regulates the expression of BCL2L11 [24] , IL7R [25] , and CTLA4 [22] and negatively regulates PDX1 [26] expression while Foxo3 induces the expression of BNIP3 [27] and inhibits ID1 [28] . IL-12 stimulation induced the downregulation of BCL2L11, IL7R, and BNIP3, and the upregulation of PDX1 and ID1, suggesting that both transcription factors were not regulating their transcriptional targets (Fig 2D) .
Activation of the PI3K/AKT/Foxo pathway induces IFNc secretion and impairs the suppressive capacity of Tregs
As the PI3K/AKT/Foxo1/3 pathway can be activated by engagement of different receptors, we hypothesized that direct activation of this pathway would be sufficient to induce the Th1-Treg phenotype independent of IL-12 or any other stimuli. To examine this hypothesis, we used a PTEN inhibitor (SF1670) [29] , an AKT activator (SC-79) [30] , a PI3K activator (740 Y-P) [31] , and a Foxo1/3 inhibitor (AS1842856) [32] . Tregs were stimulated with anti-CD3, anti-CD28, and IL-2 in the presence of these PI3K/AKT/Foxo1/3 inhibitors/ activators, and we measured TBX21 and IFNG gene expression every 24 h for a total of 3 days (Fig 3A) . The inhibitors/activators induced the predicted increase in IFNG and TBX21 gene expression based on our array data of Th1-Tregs. The increase in IFNG gene expression was confirmed at protein level by stimulating Tregs in the presence of the different activators for 3 days (Fig 3B and C) . Interestingly, all small molecules reverted the anergic-like phenotype observed in Tregs, measured by proliferation and IL-2 secretion by Tregs after activation in the presence of the molecules (Appendix Fig S2) . To confirm that activation of the PI3K/AKT/Foxo1/3 pathway induced the Th1-Treg phenotype, we pre-incubated sorted Tregs with either vehicle, SF1670, SC-79, or 740 Y-P for 1 h, washed the cells to remove traces of the drugs, and co-cultured the Tregs with CFSElabeled responder T cells (Tresp) to examine their suppressive capacity (Fig 3D and E) . While Tresp proliferation was significantly inhibited in the presence of Tregs pre-incubated with vehicle, Tregs that had been pre-incubated with either SF1670, SC-79, or 740 Y-P displayed a defect in their suppressive ability as compared to vehicle-treated Tregs (Fig 3D) , which was observed at all Treg:Tresp ratios tested (Fig 3E) .
The consequence of activation of the PI3K/AKT pathway by either activation of PI3K or AKT or inhibition of PTEN is the activation of Foxo1 and Foxo3, leading to their nuclear exclusion. Foxo1 and Foxo3 are thought to be important for Treg function and stability in mice [22] , so we pre-incubated Tregs with different doses of the Foxo1/3 inhibitor AS184256 before co-culturing with CFSElabeled Tresp to measure their suppressive capacity (Fig 4A) . Tregs pre-incubated with AS184256 displayed a decrease in suppressive function as compared to vehicle-treated Tregs in a dose-dependent manner, as the percentage of suppression was lower in those cells pre-treated with the highest concentration of AS184256 (Fig 4A and B) . This defect was observed in all Treg:Tresp ratios examined, and it was not due to an effect on Treg viability, as there were no significant differences in the frequency of viable cells after treatment with AS184256 as compared to vehicle (data not shown). To examine Data information: Data are presented as mean AE s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0005. t-test was performed for (B) and (E), and a two-way ANOVA corrected for multiple comparisons with a Sidak test for (C).
whether the defect in suppression observed was due to the increase in IFNc secretion by Tregs, as was the case in IL-12-driven Th1-Tregs [6], we examined the frequency of IFNc-secreting Tregs in the co-cultures with Tresp after being pre-incubated with AS1842856. For this purpose, after 4 days in co-culture, we added GolgiStop to the cultures for 6 h and we stained for IFNc and Foxp3 (Fig 4C) . At the time point examined, there was a significant increase in the frequency of IFNc À Tregs stimulated in the presence of vehicle or IL-12 at day 2 after stimulation (n = 8).
Data information: Data are presented as mean AE s.e.m. *P < 0.05, **P < 0.005. t-test was performed for (C) and (D). co-culture, the higher the defect in suppressive capacity ( Fig 4E) .
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To confirm these results, we used shRNAs specific for Foxo1 and Foxo3 to silence both proteins in Tregs ( Fig EV2) and measured IFNG and TXB21 gene expression. Both Foxo1 silencing and Foxo3 silencing were sufficient to induce a significant increase in IFNG and TBX21 gene expression as compared to non-target-transduced Tregs (Fig 4F) . Moreover, Foxo1-and Foxo3-silenced Tregs were defective in suppressing the proliferation of Tresp in in vitro suppression assays (Fig 4G) . These data suggest that activation of the PI3K/ AKT/Foxo1/3 pathway is sufficient to induce the Th1-Treg phenotype on human Tregs and that both Foxo1 and Foxo3 play overlapping roles in human Th1-Treg generation.
Differential role of AKT isoforms on Th1-Treg generation
Ex vivo-isolated and in vitro-generated Th1-Tregs expressed increased levels of AKT1 and decreased levels of AKT2 and AKT3 (Fig 1) , suggesting that the three isoforms may be performing non-overlapping roles in Th1-Treg generation. To examine this hypothesis, we silenced AKT1, AKT2, and AKT3 in Tregs with specific shRNA or non-target control ( Fig EV3) and we examined IFNG, TBX21, FOXP3, and IL10 expression, as we Data information: Data are presented as mean AE s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0005. Two-way ANOVA corrected for multiple comparisons with a Sidak test was performed for (A) and (E), and a t-test for (C). (Fig 5B and C) .
We next examined the suppressive capacity of AKTsilenced Tregs in co-cultures with Tresp (Fig 5D and E) . While Data information: Data are presented as mean AE s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0005. Two-way ANOVA corrected for multiple comparisons with a Sidak test was performed for (B) and (G), a one-way ANOVA with a Tukey's post-test for (D) and a t-test for (F). For correlation in (E), r was calculated by Pearson correlation coefficient.
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non-target-transduced Tregs efficiently suppressed Tresp proliferation, AKT3-silenced Tregs were defective in Tresp inhibition. We did not observe any difference in suppression between control and AKT2-silenced Tregs, but AKT1-silenced Tregs showed an increase in their suppressive capacity as compared to the control. These data suggest that AKT isoforms play non-overlapping roles on Th1-Treg generation.
Blockade of PI3K/AKT/Foxo1/3 pathway on Th1-Tregs inhibits IFNc secretion and restores Treg suppressive capacity
We then wished to examine whether blockade of the PI3K/AKT/ Foxo1/3 pathway in Th1-Tregs would inhibit IFNc and restore their suppressive capacity (Fig 6) . Tregs were stimulated in the presence of vehicle or IL-12 to generate Th1-Tregs, and 1 day later, a PI3K (LY294002) or an AKT1 inhibitor (MK2206) was added to the culture with subsequent examination of IFNG and TBX21 gene expression every 24 h for 3 days. As MK2206 can inhibit the three AKT isoforms, we used a concentration to inhibit only AKT1. Inhibition of either PI3K or AKT1 significantly decreased the expression of IFNG and TBX21 on Th1-Tregs (Fig 6A) . Data information: Data are presented as mean AE s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0005. One-way ANOVA with a Tukey's post-test was performed for (A), and a two-way ANOVA with correction for multiple comparisons for (C) and (E).
ª
partially, suggesting that AKT1 blockade is not enough to completely inhibit the Th1-Treg phenotype (Fig 6C) . Furthermore, when Th1-Tregs were pre-incubated with either LY294002 or MK2206, washed, and co-cultured with Tresp, they were able to efficiently suppress the proliferation of Tresp as compared to Th1-Tregs pre-treated with vehicle ( Fig 6D) . While AKT1 blockade improved suppression, but not to the suppressive capacity achieved by control Tregs, PI3K blockade fully restored suppression even above the suppressive capacity of control Tregs (Fig 6E) . Furthermore, treatment of in vitro-derived Th1-Tregs with MK2206 and LY294002 decreased the frequency of proliferating cells and IL-2 secretion (Appendix Fig S4) . These data suggest that the PI3K/AKT/Foxo1/3 pathway activation is necessary to maintain the Th1-Treg phenotype and function. Data information: Data are presented as mean AE s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0005. Two-way ANOVA corrected for multiple comparisons with a Sidak test performed for (A) and (E), and a one-way ANOVA with a Tukey's post-test for (C). (Fig EV4) . We then examined the expression of the differentially expressed genes in IFNc + Tregs (Fig 1) in ex vivo-isolated Tregs from RRMS and compared them to HC (Fig 7A) . A significant downregulation of PTEN, AKT3, and FOXO3 was observed while no differences were observed in the expression of AKT1, AKT2, or FOXO1. It was of interest that decreases in AKT3, PTEN, and FOXO3 were confirmed at protein level in Tregs from patients, demonstrating that these RRMS patients express less levels of the three proteins as compared to paired controls ( Fig 7B) . Furthermore, the phosphorylation status of AKT, Foxo1, and Foxo3 was significantly increased in ex vivo-isolated Tregs from RRMS patients as compared to healthy donors (Fig 7C) , suggesting that the PI3K/AKT/Foxo1/3 pathway was activated in vivo in RRMS patients.
As blockade of the PI3K/AKT/Foxo1/3 pathway restores Th1-Treg phenotype and function (Fig 6) , we hypothesized that PI3K or AKT1 inhibition in RRMS Tregs would decrease the frequency of IFNc +
Foxp3
+ Tregs and restore their suppressive capacity. Sorted
Tregs from RRMS patients and healthy controls were stimulated with anti-CD3 and anti-CD28 in the presence of either vehicle, LY294002, or MK2206 for 3 days. Intracellular staining revealed that inhibition of both PI3K and AKT1 on Tregs from RRMS patients inhibited IFNc secretion while not having any effect on Tregs from controls ( Fig 7D and E) . More importantly, when Tregs from RRMS patients were pre-incubated with LY294002 or MK2206, they were able to efficiently suppress Tresp proliferation, with LY294002 being able to restore Treg suppressive capacity above the suppressive ability of Tregs from healthy control subjects. PI3K or AKT1 blockade did not have any effect in the suppressive capacity of Tregs from healthy donors (Fig 7F and G) . Thus, our data indicates that the Th1-Treg phenotype observed in Tregs from RRMS is, at least in part, due to an in vivo activation of the PI3K/AKT/Foxo1/3 pathway, that can be corrected by PI3K or AKT1 blockade. [34] and in vivo [35] , but its role in the phenotype, function, and/or stability of established Tregs is not well understood. In this regard, it has been shown that AKT phosphorylation is defective in Tregs as compared to Tresp after TCR stimulation and this diminished activation is necessary for the Tregs to efficiently perform their suppressive function [36] . In order to examine the role of the PI3K/AKT pathway in Th1-Treg generation, we demonstrated that in vitro-generated IL-12-driven Th1-Tregs exhibit an activated PI3K/AKT/Foxo1/3 pathway, in agreement with published data suggesting the activation of AKT by IL-12 [37] . Moreover, we induced the Th1-Treg phenotype not only by IL-12-driven AKT activation, but also by simply stimulating Tregs in the presence of PI3K or AKT1 activators, or PTEN or Foxo1/3 inhibitors, in agreement with recent data highlighting the importance of the PI3K pathway and PTEN on mice Treg stability [38, 39] . In all cases, Tregs upregulated IFNc protein expression and TBX21 expression and were defective in suppressive capacity as compared to vehicle-treated Tregs.
Factors downstream of AKT activation, particularly the transcription factors Foxo1 and Foxo3, also have been reported to have Data information: Data are presented as mean AE s.e.m. *P < 0.05, **P < 0.005, ***P < 0.0005. t-test was performed for (A) and two-way ANOVA corrected for multiple comparisons with a Sidak test for (E) and (G). While most of the reports in the literature examine global AKT expression and phosphorylation, gene expression data in Th1-Tregs demonstrated upregulation of AKT1 with downregulation of AKT2 and AKT3, prompting us to examine the role of the individual isoforms in Th1-Treg generation. Interestingly, we observed that AKT1 blockade greatly inhibits Th1-Treg generation, in agreement with previous reports by Levings and coworkers [36] , while surprisingly, AKT3 silencing was sufficient to induce IFNc expression on Tregs. There are some examples where non-overlapping functions of AKT isoforms have been described [41] [42] [43] , and interestingly, a recent paper has suggested a role for AKT3 in protecting mice from EAE [44] . The choice decision for activation of one or other isoform could be determined by the stimulus that is activating the pathway, or the specific cell type being examined.
PI3K/AKT are often dysregulated in autoimmune disease, and the expression of a constitutively active form of AKT leads to autoimmunity [45, 46] . The importance of the PI3K/AKT/Foxo1/3 signaling pathway is also suggested by the fact that various murine models that demonstrate increased activity of the PI3K/AKT pathway signaling have an autoimmune phenotype (reviewed in [47] ). In MS, there are likely several signaling pathways that lead to Th1-Treg generation. The one described here can be activated by either the ex vivo downregulation of PTEN, the ex vivo increased phosphorylation of AKT, and/or the downregulation of AKT3. In relation to PTEN, it has been demonstrated that Tregs display increased levels of PTEN ex vivo, and these levels are maintained upon stimulation, in contrast to responder T cells, where it is downregulated rapidly after stimulation [48, 49] . Furthermore, PTEN deficiency in rodent Tregs upregulates IFNc and these cells are not capable of restraining Th1 and Tfh responses in vivo [38, 39] .
Th1-Tregs have not only been observed in human autoimmune diseases such as MS and type 1 diabetes [6,9], but also during viral and bacterial infections [10, 33] , suggesting that the environmental cue that induces the Th1-like phenotype could be different in each disease setting. While the emergence of Th1-Tregs in acute infection could be a physiological protective mechanism during the adaptive phase of the immune response, the increased frequency of Th1-Tregs in human autoimmune diseases is a potentially detrimental phenotype for the outcome of the disease. Nevertheless, modulation of the PI3K/AKT/Foxo1/3 pathway during these diseases could be a potential target for Treg function control.
Other signaling pathways are likely playing a role in Th1-Tregs generation (Appendix Table S1 ). Whether these pathways are acting at the same time and/or anatomical location, and their activation/ inhibition depends on different environmental cues needs further investigations. The fact that PI3K activation can be triggered by different receptor engagements supports the hypothesis that in humans, IFNc secretion and the acquisition of a Th1-Treg phenotype is a common "default" mechanism that dysfunctional Tregs adopt in several disease settings such as autoimmunity and acute infection. Nevertheless, these data identify novel targets for restoring the loss of regulatory T-cell function in patients with autoimmune disease.
Materials and Methods

Study subjects
Peripheral blood was drawn from healthy individuals and 15 subjects with relapsing-remitting MS and their age-and sexmatched controls after informed consent and approval by the Institutional Review Board at Yale University. The patients were of ages of 44.0 AE 4.1 years, and all had relapsing-remitting disease with Kurtzke Expanded Disability Status Scale scores between 0 and 2.5. All patients (n = 15) were not treated with any immunomodulatory drugs. All experiments were performed conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
Cell culture reagents and antibodies
Cells were cultured in RPMI 1640 media supplemented with 2 nM L-glutamine, 5 mM HEPES, and 100 U/lg/ml penicillin/streptomycin (Biowhittaker, Walkersville, MD), 0.5 mM sodium pyruvate, 0.05 mM nonessential amino acids (Life Technologies, Rockville, MD), and 5% human AB serum (Gemini Bio-Products, Woodland, CA). The antibodies used for stimulation were anti-human CD3 (clone UCHT1) and anti-human CD28 (clone 28.2) (BD Biosciences, San Jose, CA) at 1 lg/ml. Treg Inspector Beads (Miltenyi Biotec, Bergisch Gladbach, Germany) were used in suppression assays. IL-12 (R&D Systems, Minneapolis, MN) was used at 20 ng/ml. IL-2 was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and was used at 25 U/ml.
The PTEN inhibitor SF1670 (Echelon Biosciences, Salt Lake City, UT) was used at 500 nM [50] . The PI3K activator 740 Y-P (Tocris, Minneapolis, MN) was used at 20 lM [51,52]. The AKT activator SC-79 (EMD Millipore, Billerica, MA) was used at 4 lg/ml [53] . The Foxo1/Foxo3 inhibitor AS1842856 (EMD Millipore) was used at different concentrations ranging from 1 nM to 50 nM, as previously published [54, 55] . The PI3K inhibitor LY294002 (Invivogen, San Diego, CA) was used at 10 lM [56-58]. MK2206 (SelleckChem, Pittsburgh, PA) was used at a concentration of 5 lM, based on similar published works performed in T cells and Tregs [59, 60] , and our own titration experiments. None of the small molecules used in this work induced significant cell death at the concentrations described above (Fig EV5) .
Cell isolation and FACS sorting of T-cell populations
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donors or patients with MS after informed consent was 
Cell activation and intracellular staining
Cell populations were stimulated with 1 lg/ml plate-bound anti-CD3, 1 lg/ml soluble anti-CD28, and 25 U/ml IL-2 in the presence or absence of IL-12. At day 3, cells were stimulated with 50 nM phorbol-12-myristate-13-acetate (PMA) and 250 nM ionomycin for 4 h in the presence of GolgiStop (BD Biosciences) and intracellular staining of IFNc, and Foxp3 was performed with Foxp3 staining buffers (eBioscience) as per manufacturer's recommendations and the following antibodies: IFNc (clone 4S.B3) from Biolegend (San Diego, CA) and Foxp3 (clone PCH101) from eBioscience.
Microarray sample preparation and analysis
Tregs from healthy donors were sorted and stimulated with 50 ng PMA and 250 ng ionomycin for 4 h. IFNc detection kit (Miltenyi) was used to stain cytokine-secreting cells. Cells were resorted based on the expression of IFNc. Samples were subjected to microarray analysis on an Affymetrix platform, and the data was quantilenormalized (Bioconductor Affy package) and log2-transformed. Quality control was performed using ArrayQualityMetrics [61] , and arrays were preprocessed with RMA [62] . Differential expression was calculated using LIMMA package for single channel paired experimental design with Benjamini and Hochberg multiple testing adjustment [63] . Microarray analysis and description were carried out according to Minimum Information About a Microarray Experiment (MIAME) guidelines (GEO accession number GSE71274 [64] ). Differentially expressed genes (fold change cutoff 1.5) were clustered into signaling pathways by Ingenuity Pathway Analysis (www.ingenuity.com/products/ipa) and sorted by BioRank. BioRank is a novel way to identify pathways and is complementary to the P-value enrichment score for each pathway, which is generated using the Fisher's exact enrichment test and primarily identifies significant overlap between your DEGs and the pathways. BioRank, besides identifying significant overlap between the DEGs and pathways, identifies cases where the DEGs from the dataset play an essential role in the pathway (www.ingenuity.com/products/ipa). 
Gene silencing by lentiviral transduction
Lentiviral particles encoding shRNAs were obtained from SigmaAldrich. 10 5 sorted Tregs per well were stimulated with plate-bound anti-CD3 (1 lg/ml) and soluble anti-CD28 (1 lg/ml) for 24 h before transduction. Cells were then transduced with viral particles containing a vector expressing the indicated specific shRNA or a non-target shRNA as a control at a multiplicity of infection of 5. All constructions contained the coding sequence for GFP. After 5 days in culture, transduced cells were sorted based on GFP expression and the efficiency of gene silencing was determined by TaqMan real-time PCR and protein staining.
Analysis of phosphorylation by FACS
Treg cells were stimulated with 1 lg/ml anti-CD3 and 1 lg/ml anti-CD28 and 50 ng/ml IL-12 and fixed at different time points with fixation buffer (BD Biosciences), permeabilized with Perm Buffer III following manufacturer's recommendations, and stained with PE-labeled mouse anti-pAKT (pThr308) from BD Biosciences and pFoxo1 (pSer319) and pFoxo3 (pSer294) from Bioss. For stainings at 16 h, Tregs were stimulated with 1 lg/ml anti-CD3 and 1 lg/ml anti-CD28 in the presence of IL-12 at 50 ng/ml for 16 h. For ex vivo stainings of MS and HC Tregs, ex vivo-sorted Tregs were fixed directly after sort with fixation buffer and stained as above. The specific time points selected to examine AKT, Foxo1, and Foxo3 phosphorylation were chosen based on preliminary kinetics experiments that were performed for a total of 50 min.
Statistics
Statistical analysis was performed using GraphPad Prism (GraphPad Software). A standard paired two-tailed t-test was used for statistical analysis and a one-way ANOVA with a Tukey's post-test or a twoway ANOVA corrected for multiple comparisons with a Sidak test for more than two groups' comparisons; P-values of 0.05 or less were considered significant. Data were presented if not indicated elsewhere as mean AE s.e.m. (*P < 0.05, **P < 0.005, ***P < 0.0005). For correlation in Fig 3J, r was calculated by Pearson correlation coefficient.
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